Eslicarbazepine Acetate
Eslicarbazepine Acetate. Carbamazepine analog — voltage-gated Na+ channel slow inactivation enhancer. Active metabolite is the same… Oral half-life 13 h.
Carbamazepine analog — voltage-gated Na+ channel slow inactivation enhancer. Active metabolite is the same S-licarbazepine fraction made by oxcarbazepine. Adjunct for partial-onset seizures.
PK: AN EFFECTIVE HALF-LIFE STORED AS AN ELIMINATION HALF-LIFE — A NEW SHAPE, AND ITS SOURCE NAMES IT. "After ESL oral administration, the EFFECTIVE half-life (t(1/2,eff)) of eslicarbazepine was 20-24 h, which is approximately TWO TIMES LONGER than its terminal half-life". The stored 22 was both the midpoint of that range and the accumulation parameter that justifies once-daily dosing rather than the elimination rate a one-compartment model needs, and it ran exposure 60% high against its own citation verbatim "AUC(0-inf), 225 000 versus 234 000 ng.h/mL". Three independent lines converge on ten to thirteen hours, including a verbatim "apparent terminal half-life of 8-17h" and the fact that OXCARBAZEPINE IN THIS SAME CATALOG STORES 9 h FOR THE SAME CIRCULATING MOLECULE. The value adopted is the one reproducing that observed exposure, disclosed as derived. F 0.90 becomes the verbatim "systemic exposure to eslicarbazepine after ESL oral administration is approximately 94% of the parent dose". AND THE MASS WAS THE PRODRUG: the record modelled S-licarbazepine while storing 296.32, the ACETATE, where the circulating species is 254.29 — a 16.5% error, proven by "Plasma BIA 2-093 concentrations were generally below the limit of quantification of the assay". It has no occupancy row today, so nothing inherited the error yet. ANALYTE: the stored mass was the ACETATE PRODRUG while every PK value describes S-licarbazepine — a 16.5% error, and the largest of the four mass defects found across batches 7 and 8. Proof from its own literature: "Plasma BIA 2-093 concentrations were generally below the limit of quantification of the assay." The catalog OXCARBAZEPINE record models the same circulating molecule and carries the analogous note already; this is the same chimera, an order of magnitude larger. No occupancy row exists here yet, so nothing has inherited the error.
Pharmacokinetics
- Oral — t½ 13.2 h · F 94% · Vd 61 L
Sources: PMID:27249205, PMID:22612290, PMID:12952496